The House Energy and Commerce Health Subcommittee today held a hearing on implementation of the Compounding Quality Act, which updated federal requirements for drug compounding facilities after a 2012 fungal meningitis outbreak that was associated with a contaminated compounded steroid medication distributed to patients and providers in 23 states. Witnesses at the hearing included Food and Drug Administration Commissioner Scott Gottlieb, M.D.; officials from two companies that manufacture compounded sterile drugs; a patient; and representatives from the American Academy of Dermatology, International Academy of Compounding Pharmacists, The Pew Charitable Trusts, National Community Pharmacists Association, and American Academy of Ophthalmology. As FDA continues to implement the law, Gottlieb said the agency “plans to take steps that preserve lawful pharmacy practices and expand the opportunities for pharmacies that want to engage in larger-scale compounding to efficiently become 503B facilities.”

Related News Articles

Headline
The AHA and dozens of other organizations yesterday urged House and Senate sponsors of the Conrad State 30 and Physician Access Reauthorization Act to…
Headline
The AHA March 27 voiced opposition to the Physician Led and Rural Access to Quality Care Act (H.R. 2191), a bill that would lift the ban on the establishment…
Headline
The AHA March 11 shared ways Congress could better support patient access to post-acute care in comments for a hearing held by the House Committee on Ways and…
Headline
The House of Representatives March 11 voted 217-213 to pass a continuing resolution to fund the federal government through Sept. 30. The bill also extends…
Headline
More than 150 hospital and health system leaders March 4 participated in an AHA Advocacy Day briefing in Washington, D.C., to get the latest updates on key…
Headline
The U.S. Senate voted 52-48, after a 10-hour “vote-a-rama" session, to adopt a budget resolution for fiscal year 2025 focusing on the border, military and…